First-line immunotherapy-based regimens for metastatic non-small cell lung cancer: A network meta-analysis of landmark trials

Our analysis indicates pembrolizumab-based regimens, as monotherapy or with chemotherapy, offer the most robust and highestranking survival advantage across most key NSCLC subgroups. These findings provide a critical, evidence-based framework to guide individualized first-line treatment selection.